The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up of 15 AML1/ETO-positive children using real-time quantitative reverse transcription PCR (RQ-RT-PCR), all enrolled in the multicenter therapy trial AML-BFM 98. AML1/ ETO copy numbers were normalized to the control gene ABL and the results were expressed in copy numbers AML1/ETO per 10 000 copies ABL. At diagnosis, a median of 10 789 copies AML1/ETO was found. A linear decrease to about 10 copies (2-4 log) could be seen in most of the children by the start of consolidation. In the majority of cases they remained positive at this low level during the ongoing therapy. Four children relapsed and two of them had a decrease of less than 2 log before starting consolidation. Three of the relapsed children showed, prior to relapse, an increase of the AML1/ETO fusion transcript at 6, 9, and 11 weeks, respectively. These results suggest that monitoring of minimal residual disease using RQ-RT-PCR could be helpful in detecting patients with a higher risk of relapse.
Introduction
The reciprocal translocation t(8;21)(q22;q22) results in a fusion of the AML1 (CBFa) gene on chromosome 21 and the ETO (MTG8, CDR8) gene on chromosome 8. The chimeric AML1/ ETO fusion gene is transcribed from the derivative chromosome 8.
1,2 The chromosomal breakpoint cluster in intron 5 of AML1 and the upstream exon 2 of ETO yield to an in-frame fusion transcript. [3] [4] [5] [6] Additional, alternative out-of-frame splicing variants are described in some cases. [7] [8] [9] In childhood and adult de novo AML, the translocation t (8;21) occurs in approximately 7-12% of cases, predominantly in AML-M2. [10] [11] [12] Patients with a t(8;21) are known to have a favorable prognosis and achieve complete remission (CR) in 98%. The overall survival at 5 years is 69% for all patients, and 83% at 3 years for children. 10 Despite the good prognosis, several studies using qualitative RT-PCR have reported the persistence of the AML1/ETO fusion transcript in long-term remission after chemotherapy and autologous or allogeneic bone marrow transplantation. [13] [14] [15] On the other hand, there are some reports of patients becoming PCR negative in long-term remission. [16] [17] [18] One qualitative RT-PCR study has shown a good correlation between negative PCR results and prognosis. 19 Initial quantitative PCR assays for AML1/ETO based on competitive RT-PCR have given promising results in monitoring MRD. [20] [21] [22] One study indicates a good correlation between the level of AML1/ETO fusion transcript in remission and high risk of relapse. 21 However, this method is very time-consuming, labor intensive, limited in the dynamic range of quantification, and is therefore not suitable for routine diagnostics.
Real-time quantitative reverse transcription PCR (RQ-RT-PCR) overcomes these problems. This method is very fast, accurate, and reproducible and can therefore be used for large studies on minimal residual disease (MRD). A comparison of competitive RT-PCR and RQ-RT-PCR in patients positive for AML1/ETO showed a good correlation regarding sensitivity and reproducibility. 23 Several RQ-RT-PCR studies of patients with a AML1/ ETO fusion transcript have been published, most of which were concerned with adult AML. To the best of our knowledge only one RQ-RT-PCR study has been based on childhood AML exclusively. 24 In this study, 14 children with an AML1/ETO rearrangement were analyzed at diagnosis and during therapy. However, the children had different treatment schedules and the sampling times were designated only in terms of the number of treatment courses.
Here, we present the results of an RQ-RT-PCR study including 15 children positive for the AML1/ETO rearrangement. All of them were monitored consecutively for MRD, and they were treated uniformly according to the multicenter AML-BFM 98 protocol.
Patients and methods

Patients
In a period from July 1998 to October 2002 bone marrow (BM) or peripheral blood (PB) samples of 177 children with de novo AML (mainly M2) were screened successfully by RT-PCR for the AML1/ETO rearrangement, and 33 were found to be positive. All samples were mailed to the Oncogenetic Laboratory at the Children's Hospital, University of Giessen, from more than 60 pediatric oncology centers in Germany. All children were treated in the multicenter study AML-BFM 98. The FAB subtype was determined according to morphological and cytological criteria by the central review committee of this study group, and the immunological analysis was performed in the reference laboratory by Professor W-D Ludwig, Berlin-Buch, Germany.
From the 33 AML1/ETO-positive children, 15 (11 male, four female) were analyzed because of the available BM samples at minimally three different time points during therapy. All children were classified as AML-M2 and the last follow-up was 25.10.2002 or stopped with relapse. The median age was 9.6 years (range 5.1-17.6) and the white blood count (WBC) ranged between 2.3 and 52.0 with a median of 10.0 Â 10 9 /l.
With the exception of one patient, the presence of AML1/ETO at diagnosis was confirmed by cytogenetics (Table 1 ). All children were treated uniformly according to the protocol of the AML-BFM 98 study.
Treatment
The AML-BFM 98 study is based on the treatment schedule of the AML-BFM 93 study. 25 The first induction therapy combined 48 h continuous infusion of cytarabine (100 mg/m 2 /d), followed by cytarabine (100 mg/m 2 /d) short-term infusion every 12 h for 4 days. Idarubicin 12 mg/m 2 and etoposide 150 mg/m 2 were given at days 3, 5 and 7 and days 6-8, respectively (AIE). In children with blasts lower than 5% in BM at day 15, G-CSF interval treatment with 5 mg/kg was randomized. BM examinations were performed at diagnosis (T0) and at different time points during therapy (T1-T8) ( Table 2) .
RNA isolation and reverse transcription
Mononuclear cells were isolated from BM and PB samples using Lymphoprep (Axis-Shield, Oslo, Norway) and stored at À701C prior to use. Total RNA was extracted by a single-step method with Trizol (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions. A volume of 2-5 ml RNA (B0.2-5 mg) was reverse transcribed in a total volume of 20 ml. After denaturation at 701C for 10 min, the cDNA synthesis was carried out at 371C for 45 min using 200 U of SuperScriptt RNase H À reverse transcriptase (Invitrogen, Karlsruhe, Germany), 1 Â firststrand buffer, 10 mM DTT, 5 mM random hexamer primers (Roche Diagnostics, Mannheim, Germany), 40 U RNAsin (Promega, Mannheim, Germany), and 0.5 mM of each dNTP (Roche Diagnostics, Mannheim, Germany). Subsequently, the cDNA was heated to 951C for 5 min, to inactivate the reverse transcriptase, and stored at À201C.
Standard curves
For generation of standard curves from AML1/ETO and the control gene ABL an RT-PCR product was cloned. For ABL an m-BCR/ABL RT-PCR product containing the ABL exons a2, a3 and a part of a4 was amplified using primers m-BCR up (5 0 -GCAGAATTCGACAACCTGATCGACGCCAATGG-3 0 , underlined EcoRI linker) and ABL down (5 0 -GCAGCGGCCGC TTGTGCTTCATGGTGATGTCCGTG-3 0 . underlined Notl linker). An 1169 bp product was cloned into the pBluescript II SK(+/À) vector (Stratagene, Amsterdam Zuidoost, Netherlands). The 198 bp AML1/ETO PCR product amplified with primers D1 and U1 26 was ligated into pCRII-TOPO vector (Invitrogen, Karlsruhe, Germany). Both inserts were sequenced to confirm the expected sequence. The plasmids were linearized with NotI, treated with alkaline phosphatase, and after purifying with QIAquick PCR Purification Kit (Qiagen; Hilden, Germany) they were quantitated at 260 nm. The plasmids were diluted with H 2 O to a concentration of 10 Â 10 6 copies/ml. A 10-fold serial dilution in 1 mM Tris (pH 8.0), 0.1 mM EDTA and 50 mg/ml Escherichia coli tRNA was then performed to obtain standard curves ranging from 1 Â 10 6 to 10 copies/ml. 27 The dilutions were aliquoted and stored at À201C prior to use.
Primer and probes
Real-time quantification was performed with the fluorescent TaqMan technology, which uses an oligonucleotide probe labeled with two fluorochromes (5 0 reporter fluorescent dye-FAM; 3 0 quencher fluorescent dye-TAMRA). Primers and probes for AML1/ETO and ABL were designed with the Primer Express software (Applied Biosystems, Foster City, USA) and synthesized by Applied Biosystems (Weiterstadt, Germany). The amplicon size was 118 bp for AML1/ETO and 92 bp for ABL (Table 3) .
Real-time quantitative RT-PCR (RQ-RT-PCR)
The AML1/ETO and the control gene ABL were amplified separately from the same cDNA.
The RQ-RT-PCR was carried out in a total volume of 25 ml containing 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems Weiterstadt, Germany), 300 nM of each primer, 200 nM of ABL or 100 nM of AML1/ETO probe (Applied Biosystems Weiterstadt, Germany), and 1 ml cDNA. For standard curve, no amplification control (NAC), and no template control (NTC) 1 ml of plasmid, cDNA of a negative cell line or H 2 O was used, respectively. All analyses were done in duplicate. The reaction conditions were 2 min at 501C for AmpErase s UNG treatment (prevents the reamplification of carryover PCR products), 10 min at 951C (inactivation of UNG and activation of AmpliTaq s Gold Polymerase), followed by 50 cycles of 15 s at 951C (denaturation) and 1 min at 601C (annealing and extension). All reactions were performed on the ABI PRISM s 7700 Sequence Detection System (Applied Biosystems, Foster City, USA).
Control gene
To compensate variations of RNA integrity and differences in the RT step the AML1/ETO fusion transcript was normalized to a control gene.
The ABL gene was chosen in view of the results of the 'Europe Against Cancer (EAC) Program'. 28 Further information about the EAC program can be obtained at the following website: http:// 194.214.97.12/scripts/defaultIE.asp. The expression of ABL was similar in PB and BM from different leukemias and samples of 
Sensitivity and specificity
The absolute sensitivity of the assays was determined using the plasmid standard curves. Additionally, a 10-fold serial dilution of 1 million Kasumi-1 cells in cells of the negative cell line HL60 was used for the AML1/ETO assay to test the sensitivity of cDNA. 29, 30 To test the specificity of this assay cDNA of four patients (one AML, one CML, one ALL, one JMML) without a t(8;21) and one healthy blood donor were analyzed. Furthermore, human genomic DNA was tested in parallel for AML1/ETO and ABL.
Evaluation of RQ-RT-PCR
The absolute copy numbers of AML1/ETO and ABL were calculated using the corresponding standard curve. For each patient, the AML1/ETO fusion transcript was normalized to the ABL fusion transcript and the value was expressed in copy numbers AML1/ETO per 10 000 ABL copies, based on the work of the 'Europe Against Cancer Program'. 31 To compare RQ-RT-PCR assays from different plates, the threshold was set at 0.1 and the baseline at 3-12 for AML1/ETO and ABL.
All samples were analyzed in duplicate and were tested in parallel with the more sensitive nested RT-PCR, routinely. If only one of the duplicate was positive, the RQ-RT-PCR analysis was assessed as positive, because of the positive RT-PCR result. In the case of a negative result of the nested RT-PCR, the RQ-RT-PCR was repeated to avoid a false-positive result because of contamination in one of the duplicates.
Samples with fewer than 2000 copies of ABL (corresponding to a C t value of 27.5-28.5) were not evaluated, if AML1/ETO was negative. Increase or decrease 41 log during therapy is deemed to be confirmed. Owing to the variance inherent in the method, an increase or decrease up to 0.5 log will be assessed as the same level of MRD, and the same applies to an increase or decrease below 10 copies AML1/ETO per 10 000 copies ABL, because of a greater methodological variation limit in this range. An increase or decrease in the range of 0.5-1 log takes an intermediate position and will be defined as an unconfirmed increase or decrease. 32 
Results
The absolute sensitivity of RQ-RT-PCR for the control gene ABL and AML1/ETO was determined by the 10-fold serial dilution of the appropriate plasmid. For both assays, 10 copies could reliably be detected. Based on cDNA a dilution of the cell line Kasumi-1 reached a sensitivity of 1:10 5 for AML1/ETO. No unspecific amplifications for AML1/ETO was observed with the t(8;21)-negative patients, the healthy donor blood, or the human genomic DNA. Also, there was no amplification of the control gene ABL with human genomic DNA.
All positive results of the RQ-RT-PCR were confirmed with the more sensitive nested RT-PCR with the exception of time point 2 (T2) from patient 7. This patient showed a positive result in one of the duplicates and a negative result with the nested RT-PCR. The repetition of the RQ-RT-PCR was negative, also a repetition of the nested RT-PCR. Therefore, the time point T2 from this patient was assessed as negative.
For standard curve analyses only the values from 1 Â 10 6 to 100 copies were used. The value of 10 copies was used as amplification control and to ensure the sensitivity of each assay. A good linearity and reproducibility of the standard curves could be obtained from ABL and AML1/ETO assays. The standard curves showed a correlation coefficient of 0.997-1.0 with a slope of À3.53 for ABL (range À3.39 to À3.60) and À3.50 for AML1/ETO (range À3.41 to À3.55).
At diagnosis, all 15 children were analyzed successfully with RQ-RT-PCR. A total of 92 follow-up samples of these patients including four relapses were analyzed and a successful result was obtained from 84 (91%). The median follow-up was 71 weeks (range 31-131). The number of AML1/ETO copies ranged between 5188 and 29 173 with a median of 9816 per 10 000 ABL copies, and no correlation with the percentage of blasts could be seen (Table 1) . In relapse, patient 1 had 41%, patient 3 7%, patient 9 50%, and patient 14 91% blasts in BM, with 4176, 481, 23 844, and 8366 copies AML1/ETO, respectively.
From the start of therapy until the beginning of consolidation, a decrease of 2-4 log of the AML1/ETO fusion transcript was registered in most of the children (11/15) . The expression level of AML1/ETO was reduced in these patients to about 10 copies or less (Figure 1 ). From the remaining four, patients 1 and 14 showed a decrease of less than 2 log at time point 3 (T3) and both children relapsed. From the other two patients (pts. 10 and 5) no samples were available at T3. After the start of consolidation most of the patients remained positive at a low level (o10 copies). At different time points during the course of disease seven patients reached the detection limit of RQ-RT-PCR. Patient 7 became negative very early (before HAM) and was also negative before HD/VP. Unfortunately, samples between these two time points are missing. Whereas one child was not analyzed after the first time point of negativity (pt. 6), five others became positive again: one switched back from positivity to negativity (pt. 12), three children were not analyzed after the first time of positivity (pts. 2, 5, and 13), and the fifth relapsed after one time point of positivity (pt. 3). Patient 15 received treatment according the therapy protocol only until T4 (during consolidation) because of hemophagocytosis. This child, however, is still in CR showing an AML1/ETO copy number below 10.
Four patients of this series relapsed: In patient 3, a normal decrease of the expression level was detected during the course of treatment and 1 year after diagnosis he was found to be negative. During maintenance therapy at day 651, however, the expression level rose to 38 copies and he relapsed 11 weeks later with an increase to 481 copies. A normal decrease to a level of about 10 copies was also found for patient 9. However, 1 year after diagnosis an increase to 1514 copies became obvious and the patient relapsed 6 weeks later (23 844 copies). The third relapse patient (pt. 14) had a high expression at T3, but showed a decrease to one copy at T6, 20 weeks before relapse (8366 copies). A high expression at T3 was also detected for patient 1, but she never reached the low copy number of 10 before consolidation. The AML1/ETO fusion transcript rose to 439 copies 9 weeks before a clinical relapse became obvious (day 235; 4176 copies).
Also patient 10 never reached an expression level below 10 copies, but samples from T3 and T4 were not available. Before HD/VP (T5), 30 copies were still detected, and after this block (T6) the copy number rose to 103. This patient is still in CR, but a close follow-up is needed.
Discussion
Despite the relatively favorable prognosis of patients with t(8;21) or AML1/ETO rearrangement, some of the children relapse or die during or after treatment. Up to now, it is impossible by morphology, immunophenotyping, or cytogenetics to identify those children with a relatively high risk of therapy failure. However, RQ-RT-PCR is able to identify a small amount of residual leukemic cells and might be a reasonable tool for follow-up monitoring.
Previously several studies based on qualitative, competitive, and RQ-RT-PCR have demonstrated the prognostic significance Figure 1 Normalized copy numbers of the AML1/ETO fusion transcript from 15 children during the therapy of the AML-BFM 98 study. For more information about the time points (T) of BM aspiration during the therapy see Table 2 . T6a, T7a, T8a, and T8b are additional BM aspirations not described in the therapy protocol. The rectangle shows the area of low positivity (about 10 copies or less) of patients after the start of consolidation. The numbers give the absolute copies of the control gene ABL to indicate sensitivity. Dashed lines connect nonconsecutive time points. d, day. of these techniques. However, the number of patients in all these reports is small, most of them are adults, and in most cases patients are neither analyzed consecutively nor treated uniformly. 19, 21, 23, [33] [34] [35] [36] [37] This study presents 15 children with AML1/ ETO rearrangement, who were analyzed by RQ-RT-PCR at diagnosis and at a minimum of four different time points during follow-up. All of them were treated according the AML-BFM 98 treatment protocol. At diagnosis, the expression level of AML1/ETO ranges between 5188 and 29 173 copies and no correlation with the percentage of blasts in the BM was detectable. The reason for this phenomenon, which has also been described by others, is still unclear. 38 Similar variations, however, were found for CBFb/MYH11 and TEL/AML1. 39, 40 In addition, no correlation could be seen with other clinical parameters like WBC, age, and cytogenetics (Table 1) .
After the induction therapy and before starting consolidation, all children of this series reached CR, and AML1/ETO expression decreased rapidly. However, most of them remained positive for the transcript on a low level during the ongoing therapy. Similar results were obtained by Kondo et al. 24 They reported a decrease from a corrected AML1/ETO expression level of median 1.5 at diagnosis to median 4.5 Â 10 À3 1 month later in eight children, and most of them remained positive during follow-up. In addition, several RQ-RT-PCR studies describe a linear decrease of AML1/ETO for adults in the range of 2-4 log between diagnosis and CR, and some of them remained positive during the ongoing therapy. 23, [33] [34] [35] [36] [37] Some children in our study turned from a negative RQ-RT-PCR result to positivity with a low copy number in the next follow-up sample (pts. 2, 5, 12, 13). The reason for this increase of expression could be a variation of sensitivity in samples with low copy numbers. As shown in Figure 1 , these four patients had a two-to seven-fold higher absolute copy number of the control gene ABL in the low positive samples. However, it can also be because of a normal turnover in the residual cells or therapy effects. On the other hand, this increase might also be the first step of a beginning relapse (pt. 3).
Patients 1 and 14, who relapsed in our study, had a high expression level before consolidation compared to most of the other patients. Interestingly, in the study of Kondo et al 24 the child with the highest expression level 1 month after diagnosis relapsed, and Marcucci et al 36 described one adult with a high level of AML1/ETO during therapy and subsequent relapse. Unfortunately, no sample of T3 was available from patient 10 of our study, but he shows a higher expression level in all following analyses than the other children, but is still in CR and has not yet relapsed. The follow-up of this child will be very interesting and will help to answer the question whether the level of AML1/ETO expression at different time points during therapy could be a general prognostic factor. Interestingly, a recent RQ-RT-PCR study on adults positive for CBFB/MYH11 [inv (16) ] has shown that most of the patients (4/5) with more than 100 normalized CBFB/MHY11 copies after induction had a relapse, whereas patients below this level never relapse. 41 Similar results were reported from Buonamici et al. 42 All four relapse patients of our study were randomized in different therapy trials. In three of them an increase of the AML1/ ETO fusion transcript became obvious 9 weeks (pt. 1), 11 weeks (pt. 3), and 6 weeks (pt. 9) prior to relapse. Similar results were reported from adults with an AML1/ETO rearrangement. Using competitive RT-PCR, Tobal et al 21 showed a significant increase in the level of AML1/ETO transcripts 3-6 months before relapse. In one RQ-RT-PCR study, a rapid increase of the AML1/ETO fusion transcript during CR after BM transplantation was observed, and the patient relapsed 10 weeks later. 35, 38 On the other hand, no rapid increase could be seen before relapse by other investigators. 33, 36, 37 This difference could be because of the fact that only a few data were available from the remission phase before relapse. Also, our patient 14 showed no increase prior to relapse, but the interval of 20 weeks between last follow-up analysis and relapse was much longer than in all our relapse patients indicating the relevance of a close follow-up.
The results of this and other studies show that RQ-RT-PCR is a powerful tool for disease monitoring of AML1/ETO-positive patients. This method is very fast, accurate and reproducible, with a high dynamic range of quantification, and is therefore very suitable for prospective routine diagnosis. However, a regular screening at short intervals is needed for early relapse prediction, but in the AML-BFM 98 study the period between the obligate bone marrow aspiration (Table 2) after T6 is more than 3 months. This problem could be solved by MRD analyses of PB samples as already described by Tobal et al. 21 First preliminary data from our laboratory show promising results, but whether blood samples can be used for a close meshed MRD screening in childhood AML has to be shown.
The assessment of the AML1/ETO expression level might be helpful in identifying patients with a higher relapse risk. However, more uniformly treated patients and consecutively assembled follow-up data are needed to draw conclusions about its prognostic relevance.
